Immune-Related Adverse Events: A Case-Based Approach

Immunotherapy has heralded the advent of a new era in oncology. Immune checkpoint inhibitors (ICIs) enhance anti-tumor immunity, thereby reinvigorating a patient's immune system to fight cancer. While therapy with this class of agents has resulted in improved clinical outcomes for patients with...

Full description

Bibliographic Details
Main Authors: Caoilfhionn Connolly, Kalindi Bambhania, Jarushka Naidoo
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-06-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00530/full
id doaj-7d6e83b73b884e49b46c57f1cbaddfc5
record_format Article
spelling doaj-7d6e83b73b884e49b46c57f1cbaddfc52020-11-24T21:41:03ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2019-06-01910.3389/fonc.2019.00530463691Immune-Related Adverse Events: A Case-Based ApproachCaoilfhionn Connolly0Kalindi Bambhania1Jarushka Naidoo2Jarushka Naidoo3Department of Internal Medicine, Johns Hopkins Hospital, Baltimore, MD, United StatesDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, United StatesDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, United StatesDepartment of Oncology, Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, MD, United StatesImmunotherapy has heralded the advent of a new era in oncology. Immune checkpoint inhibitors (ICIs) enhance anti-tumor immunity, thereby reinvigorating a patient's immune system to fight cancer. While therapy with this class of agents has resulted in improved clinical outcomes for patients with multiple tumor types, a broad spectrum of immune-related adverse events (irAEs) may affect any organ system, with variable clinical presentations. Prompt recognition and management of irAEs are associated with improved irAE outcomes, and represents an important new clinical challenge for practicing oncologists. Herein, we provide a comprehensive case-based review of the most common and clinically-important irAEs, focussing on epidemiology, clinical manifestations, and management. We also examine future strategies that may provide meaningful insights into the prevention and management of irAEs.https://www.frontiersin.org/article/10.3389/fonc.2019.00530/fullimmune checkpoint inhibitorsimmune-related adverse eventsimmunotherapyimmune-related toxicitiesmanagement
collection DOAJ
language English
format Article
sources DOAJ
author Caoilfhionn Connolly
Kalindi Bambhania
Jarushka Naidoo
Jarushka Naidoo
spellingShingle Caoilfhionn Connolly
Kalindi Bambhania
Jarushka Naidoo
Jarushka Naidoo
Immune-Related Adverse Events: A Case-Based Approach
Frontiers in Oncology
immune checkpoint inhibitors
immune-related adverse events
immunotherapy
immune-related toxicities
management
author_facet Caoilfhionn Connolly
Kalindi Bambhania
Jarushka Naidoo
Jarushka Naidoo
author_sort Caoilfhionn Connolly
title Immune-Related Adverse Events: A Case-Based Approach
title_short Immune-Related Adverse Events: A Case-Based Approach
title_full Immune-Related Adverse Events: A Case-Based Approach
title_fullStr Immune-Related Adverse Events: A Case-Based Approach
title_full_unstemmed Immune-Related Adverse Events: A Case-Based Approach
title_sort immune-related adverse events: a case-based approach
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2019-06-01
description Immunotherapy has heralded the advent of a new era in oncology. Immune checkpoint inhibitors (ICIs) enhance anti-tumor immunity, thereby reinvigorating a patient's immune system to fight cancer. While therapy with this class of agents has resulted in improved clinical outcomes for patients with multiple tumor types, a broad spectrum of immune-related adverse events (irAEs) may affect any organ system, with variable clinical presentations. Prompt recognition and management of irAEs are associated with improved irAE outcomes, and represents an important new clinical challenge for practicing oncologists. Herein, we provide a comprehensive case-based review of the most common and clinically-important irAEs, focussing on epidemiology, clinical manifestations, and management. We also examine future strategies that may provide meaningful insights into the prevention and management of irAEs.
topic immune checkpoint inhibitors
immune-related adverse events
immunotherapy
immune-related toxicities
management
url https://www.frontiersin.org/article/10.3389/fonc.2019.00530/full
work_keys_str_mv AT caoilfhionnconnolly immunerelatedadverseeventsacasebasedapproach
AT kalindibambhania immunerelatedadverseeventsacasebasedapproach
AT jarushkanaidoo immunerelatedadverseeventsacasebasedapproach
AT jarushkanaidoo immunerelatedadverseeventsacasebasedapproach
_version_ 1725923486622285824